Home > In process > Longitudinal changes of blood β-synuclein in cognitively unimpaired, mild cognitive impairment and sporadic Alzheimer´s disease. > print

001     285455
005     20260305170318.0
024 7 _ |a 10.1186/s13195-026-01973-1
|2 doi
024 7 _ |a pmid:41673920
|2 pmid
024 7 _ |a pmc:PMC12930813
|2 pmc
037 _ _ |a DZNE-2026-00237
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Oeckl, Patrick
|0 P:(DE-2719)9001560
|b 0
|e First author
245 _ _ |a Longitudinal changes of blood β-synuclein in cognitively unimpaired, mild cognitive impairment and sporadic Alzheimer´s disease.
260 _ _ |a London
|c 2026
|b BioMed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1772726512_2499
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a β-Synuclein is an emerging synaptic blood biomarker for Alzheimer´s disease (AD) and correlates with cognitive impairment, brain atrophy and amyloid/tau pathology. Longitudinal data from individual patients are missing so far but are important to evaluate how changes of β-synuclein might be used in early diagnosis, prediction, disease progression and treatment monitoring.In this observational study, we investigated serum β-synuclein by immunoprecipitation-mass spectrometry (IP-MS) in 463 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) including clinically diagnosed cognitively unimpaired, mild cognitive impairment (MCI) and AD dementia subjects with ≥ 1 follow-up samples for 235 individuals and clinical follow-up for up to 19 years. CSF AD biomarker levels were available for 194 participants.Participants (40.0% female, n = 185) had a mean (± SD) age of 76.2 ± 6.7 years. The cross-sectional group comparison yielded higher β-synuclein levels in MCI and AD dementia compared with CU and in AD dementia vs MCI patients. Mean follow-up time of longitudinal serum samples was 2.3 ± 1.2 years. The longitudinal data indicate that β-synuclein levels are dynamic during all stages of the AD continuum (CU, MCI, dementia) with substantial inter-individual variation. β-Synuclein predicted MCI-to-dementia conversion and future cognitive decline and it performed better in discrimination of AD dementia patients than CSF neurogranin.Our longitudinal data support the use of serum β-synuclein levels for prediction of future cognitive decline and MCI-to-dementia conversion but needing confirmation. Further studies with biologically and clinically defined participants must verify the trajectories of β-synuclein during the AD continuum.The online version contains supplementary material available at 10.1186/s13195-026-01973-1.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Blood biomarker
|2 Other
650 _ 7 |a Longitudinal observation
|2 Other
650 _ 7 |a Mild cognitive impairment
|2 Other
650 _ 7 |a Sporadic Alzheimer´s disease
|2 Other
650 _ 7 |a Synaptic degeneration
|2 Other
650 _ 7 |a β-synuclein
|2 Other
700 1 _ |a Abu-Rumeileh, Samir
|0 0000-0003-0631-8506
|b 1
700 1 _ |a Weise, Christopher M
|b 2
700 1 _ |a Otto, Markus
|0 0000-0003-4273-4267
|b 3
700 1 _ |a Initiative, Alzheimer’s Disease Neuroimaging
|b 4
|e Collaboration Author
773 _ _ |a 10.1186/s13195-026-01973-1
|g Vol. 18, no. 1, p. 45
|0 PERI:(DE-600)2506521-X
|n 1
|p 45
|t Alzheimer's research & therapy
|v 18
|y 2026
|x 1758-9193
856 4 _ |u https://pub.dzne.de/record/285455/files/DZNE-2026-00237.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/285455/files/DZNE-2026-00237.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9001560
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS RES THER : 2022
|d 2025-11-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2025-11-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2025-08-21T13:53:36Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2025-08-21T13:53:36Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Peer review
|d 2025-08-21T13:53:36Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-11-06
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-11-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-11-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-06
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-06
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ALZHEIMERS RES THER : 2022
|d 2025-11-06
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-11-06
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-11-06
920 1 _ |0 I:(DE-2719)5000073
|k AG Öckl
|l Translational Mass Spectrometry and Biomarker Research
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)5000073
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21